Deleobuvir

Drug Profile

Deleobuvir

Alternative Names: BI-207127; BI-207127 NA; BI0207127

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class Amides; Antivirals; Benzimidazoles; Carboxylic acids; Cyclobutanes; Cyclopentanes; Indoles; Pyrimidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 31 May 2016 Boehringer Ingelheim terminates a phase I trial in Healthy volunteers in Germany prior to May 2016 (NCT01983566)
  • 01 Mar 2016 Boehringer Ingelheim terminates a phase I drug interaction study in healthy premenopausal female volunteers in Germany (NCT01941615)
  • 01 Mar 2016 Boehringer Ingelheim terminates phase I pharmacokinetics trial in patients with renal impairment, in Germany (NCT01957657)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top